Enveric Biosciences, Inc.
ENVB
$1.21
-$0.08-6.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 80.67% | -4.78% | |||
| Depreciation & Amortization | -2.71% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 52.35% | 9.76% | |||
| Operating Income | -52.35% | -9.76% | |||
| Income Before Tax | -51.03% | -10.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -51.37% | -10.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -51.37% | -10.89% | |||
| EBIT | -52.35% | -9.76% | |||
| EBITDA | -54.69% | -10.21% | |||
| EPS Basic | -33.60% | 3.32% | |||
| Normalized Basic EPS | -33.30% | 3.32% | |||
| EPS Diluted | -33.60% | 3.32% | |||
| Normalized Diluted EPS | -33.30% | 3.32% | |||
| Average Basic Shares Outstanding | 13.31% | 14.69% | |||
| Average Diluted Shares Outstanding | 13.31% | 14.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||